site:www.thepharmaletter.com - 搜索图片

700 x 466 · jpeg
www.thepharmaletter.com
Resolution Therapeutics scores £63.5 million in series B round ...
700 x 466 · jpeg
www.thepharmaletter.com
Data show diabetes delayed by tirzepatide treatment | Pharmaceutica…
700 x 466 · jpeg
www.thepharmaletter.com
EC approves Astellas’ Padcev for added indication | Pharmaceutical ...
700 x 467 · jpeg
www.thepharmaletter.com
2nd-qtr 2024 Gilead financials beat expectations | Biotechnology | The ...

700 x 466 · jpeg
www.thepharmaletter.com
Broader label for GSK's Arexvy after new European nod | Pharmaceutical ...
700 x 466 · jpeg
www.thepharmaletter.com
Strategic overhaul at Acelyrin after late-stage success | Biotechnology ...
700 x 466 · jpeg
www.thepharmaletter.com
Trailhead Biosystems appoints new chief commercial officer ...
700 x 466 · jpeg
www.thepharmaletter.com
Carvykti achieves multiple myeloma landmark | The Pharmaletter

700 x 466 · jpeg
www.thepharmaletter.com
ESMO 2024: Novartis’ Kisqali shows deepening benefit beyond three-year ...
700 x 466 · jpeg
www.thepharmaletter.com
Seattle start-up ZipBio to use AI for gene therapies | Biotechnology ...
700 x 466 · jpeg
www.thepharmaletter.com
Showing of strength of AstraZeneca’s Airsupra in asthma | The Pharmaletter
700 x 466 · jpeg
www.thepharmaletter.com
Adaptin Bio emerges with big claims on blood-brain barrier | The ...

700 x 466 · jpeg
www.thepharmaletter.com
Now GLP-1 agonists appear to reduce cancer risk for patients ...
700 x 466 · jpeg
www.thepharmaletter.com
Kedrion and Biotest agree US distribution deal for Yimmugo ...
700 x 466 · jpeg
www.thepharmaletter.com
ESMO 2024: Merck & Co keeps Keytruda data coming | The Pharmal…
700 x 466 · jpeg
www.thepharmaletter.com
FDA guidance for industry on ANDA submissions | Generics | The ...

700 x 466 · jpeg
www.thepharmaletter.com
Regeneron’s Libtayo shows strong survival rates in lung cancer ...
700 x 466 · jpeg
www.thepharmaletter.com
Zephyrm files for Hong Kong IPO to fund cell therapy work ...
700 x 466 · jpeg
www.thepharmaletter.com
Innovent partners with ASK to bring new cancer drug to China ...
700 x 466 · jpeg
www.thepharmaletter.com
New RNA manufacturing firm has focus on Asia-Pacific region ...

700 x 466 · jpeg
www.thepharmaletter.com
AAVantgarde Bio appoints new chief medical officer | Biotechnology ...
700 x 466 · jpeg
www.thepharmaletter.com
New asthma indication approved by FDA for Trelegy Ellipta | The ...
700 x 466 · jpeg
www.thepharmaletter.com
Novo Nordisk settles patent lawsuit over Ozempic | Generics | The ...
700 x 466 · jpeg
www.thepharmaletter.com
Positive Phase III data on AstraZeneca and Daiichi Sankyo’s datopotamab ...

700 x 466 · jpeg
www.thepharmaletter.com
Bad start for Moderna’s first marketed therapy outside COVID-19 ...
700 x 466 · jpeg
www.thepharmaletter.com
BRIEF—Sirnaomics secures $7.5 million in share subscription ...
700 x 466 · jpeg
www.thepharmaletter.com
Blenrep back from the brink with more positive Phase III data ...
700 x 466 · jpeg
www.thepharmaletter.com
Mixed but encouraging results for Lilly's donanemab in Alzheimer's ...

700 x 466 · jpeg
www.thepharmaletter.com
Biogen’s aducanumab aims to be first DMT approved in 17 years for Alzh ...
700 x 466 · jpeg
www.thepharmaletter.com
Chugai debuts its new NMOSD drug Enspryng in Japan | The Pharmaletter
700 x 466 · jpeg
www.thepharmaletter.com
Second historic Niemann-Pick disease nod from US FDA | Pharmaceutical ...
700 x 466 · jpeg
www.thepharmaletter.com
With second DoJ charge in as many weeks, Teva is in trouble again ...

700 x 466 · jpeg
www.thepharmaletter.com
EC approves Takeda’s Livtencity | The Pharmaletter
700 x 500 · jpeg
www.thepharmaletter.com
Boosting crinecerfont, Neurocrine draws from gamut of FDA support ...
700 x 466 · jpeg
www.thepharmaletter.com
The week in pharma: action, reaction and insight – week to September 6 ...

某些结果已被隐藏，因为你可能无法访问这些结果。显示无法访问的结果